CN1162156C - 奥氮平与氟西汀在制备治疗精神病药物中的用途 - Google Patents

奥氮平与氟西汀在制备治疗精神病药物中的用途 Download PDF

Info

Publication number
CN1162156C
CN1162156C CNB971981132A CN97198113A CN1162156C CN 1162156 C CN1162156 C CN 1162156C CN B971981132 A CNB971981132 A CN B971981132A CN 97198113 A CN97198113 A CN 97198113A CN 1162156 C CN1162156 C CN 1162156C
Authority
CN
China
Prior art keywords
fluoxetine
olanzapine
purposes
psychosis
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB971981132A
Other languages
English (en)
Chinese (zh)
Other versions
CN1230886A (zh
Inventor
Fp
F·P·拜马斯特
K·W·佩尔赖
�ж��շ�ɭ
G·D·托尔勒夫森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN1230886A publication Critical patent/CN1230886A/zh
Application granted granted Critical
Publication of CN1162156C publication Critical patent/CN1162156C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNB971981132A 1996-09-23 1997-09-09 奥氮平与氟西汀在制备治疗精神病药物中的用途 Expired - Lifetime CN1162156C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2688496P 1996-09-23 1996-09-23
US60/026,884 1996-09-23

Publications (2)

Publication Number Publication Date
CN1230886A CN1230886A (zh) 1999-10-06
CN1162156C true CN1162156C (zh) 2004-08-18

Family

ID=21834363

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB971981132A Expired - Lifetime CN1162156C (zh) 1996-09-23 1997-09-09 奥氮平与氟西汀在制备治疗精神病药物中的用途

Country Status (29)

Country Link
US (1) US6147072A (OSRAM)
EP (1) EP0830864B9 (OSRAM)
JP (1) JP2001503031A (OSRAM)
KR (1) KR100532901B1 (OSRAM)
CN (1) CN1162156C (OSRAM)
AR (1) AR008462A1 (OSRAM)
AT (1) ATE231724T1 (OSRAM)
AU (1) AU719033C (OSRAM)
BR (1) BR9711530A (OSRAM)
CA (1) CA2264941C (OSRAM)
CO (1) CO4900058A1 (OSRAM)
CZ (1) CZ301154B6 (OSRAM)
DE (1) DE69718731T2 (OSRAM)
DK (1) DK0830864T3 (OSRAM)
EA (1) EA001317B1 (OSRAM)
EG (1) EG24660A (OSRAM)
ES (1) ES2191152T3 (OSRAM)
HU (1) HU228178B1 (OSRAM)
IL (2) IL128730A0 (OSRAM)
MY (1) MY125564A (OSRAM)
NO (1) NO319166B1 (OSRAM)
NZ (1) NZ334168A (OSRAM)
PE (1) PE110198A1 (OSRAM)
PL (1) PL190374B1 (OSRAM)
RS (1) RS49828B (OSRAM)
TW (1) TW541178B (OSRAM)
UA (1) UA62937C2 (OSRAM)
WO (1) WO1998011897A1 (OSRAM)
ZA (1) ZA977967B (OSRAM)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
RU2222329C2 (ru) * 1998-04-24 2004-01-27 Скариста Лимитед Лечение депрессии и фармацевтические препараты для этой цели
CZ20004279A3 (cs) * 1998-05-22 2001-09-12 Eli Lilly And Company Lék pro léčení nepoddajné deprese a farmaceutická kompozice
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
CZ20004280A3 (cs) * 1998-05-29 2001-09-12 Eli Lilly And Company Lék pro léčbu bipolárních poruch a farmaceutický prostředek
AU1321900A (en) * 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
CA2352611A1 (en) * 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CA2367402C (en) 1999-03-12 2010-11-23 Basf Aktiengesellschaft Stable pharmaceutical dosage form for paroxetine anhydrate
JP2002544223A (ja) * 1999-05-12 2002-12-24 ソルベイ・フアーマシユーチカルズ・ベー・ブイ 精神病性障害の治療方法
CA2363784A1 (en) * 1999-05-19 2000-11-30 Astrazeneca Ab Method of treatment
AU4973800A (en) * 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
CA2385749A1 (en) * 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AU3789901A (en) 1999-12-17 2001-06-25 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
AU2001268055A1 (en) * 2000-06-30 2002-01-14 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
EP1353675A2 (en) * 2001-01-02 2003-10-22 PHARMACIA & UPJOHN COMPANY New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
WO2002062346A1 (en) * 2001-02-06 2002-08-15 Astrazeneca Ab Method of treating substance abuse with quetiapine
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
KR20040030609A (ko) * 2001-05-01 2004-04-09 하. 룬트벡 아크티에 셀스카브 경상이성체성 순수 에스시탈로프람의 용도
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
KR100842694B1 (ko) 2002-12-27 2008-07-01 오쓰까 세이야꾸 가부시키가이샤 기분 장애 치료용 카르보스티릴 유도체 및 세로토닌 재흡수억제제
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05012391A (es) * 2003-05-16 2006-02-02 Pfizer Prod Inc Tratamiento de trastornos psicoticos y depresivos.
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
JP2007522095A (ja) * 2003-05-16 2007-08-09 ファイザー・プロダクツ・インク ジプラシドンを用いた不安の治療
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
PL1708790T3 (pl) 2003-12-02 2010-10-29 Pharmaneuroboost N V Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA2550650A1 (en) * 2003-12-23 2005-07-14 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
JP5306599B2 (ja) * 2004-01-12 2013-10-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 長期間送達製剤
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EP1830844A1 (en) * 2004-12-27 2007-09-12 Alpha 2 Pharmaceutical AB Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US20070093471A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals, Llc Compositions and methods for the administration clozapine formulations which modulate body weight
US9095519B2 (en) * 2007-02-09 2015-08-04 Alphapharm Pty Ltd Dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
RU2508106C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
RU2508096C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
JP5460594B2 (ja) * 2007-08-03 2014-04-02 リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法
EP2240173A4 (en) * 2008-01-25 2013-07-17 Alphapharm Pty Ltd PHARMACEUTICAL COMPOSITION OF DULOXETINE WITH DELAYED RELEASE
WO2011018801A2 (en) * 2009-08-12 2011-02-17 Genepharm India Pvt Ltd Solid oral dosage form of ziprasidone
EP2496079A4 (en) * 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US20160310524A1 (en) * 2013-12-13 2016-10-27 Ralph Ankenman Compositions and methods for treating dysregulated systems
JP6718376B2 (ja) 2014-02-07 2020-07-08 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 抗精神病薬物およびｖｍａｔ２阻害剤を含む医薬組成物およびその使用
HUE053872T2 (hu) 2015-10-30 2021-07-28 Neurocrine Biosciences Inc Valbenazin-ditozilát és polimorfjai
MA44127A (fr) 2015-12-23 2018-10-31 Neurocrine Biosciences Inc Procédés de synthèse pour la préparation de di(4-méthylbenzènesulfonate) de 2-amino-3-méthylbutanoate de (s)-(2r,3r,11br)-3-isobutyl-9,10-diméthoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1,-a]isoquinoléin-2-yl
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
KR20200066662A (ko) 2017-01-27 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
IL309802A (en) 2017-09-21 2024-02-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
MY198713A (en) 2017-10-10 2023-09-19 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MA53239A (fr) 2018-08-15 2022-05-04 Neurocrine Biosciences Inc Procédés d'administration de certains inhibiteurs de vmat2
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108938635A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种低剂量非典型抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
EP0906104A4 (en) * 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
WO1997035586A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
US5846928A (en) * 1996-08-01 1998-12-08 Pasken Products Co., Ltd. Method for treating cancer patients
US5877198A (en) * 1996-10-17 1999-03-02 Milkhaus Laboratory, Inc. Treatment of urinary incontinence

Also Published As

Publication number Publication date
IL128730A0 (en) 2000-01-31
EA001317B1 (ru) 2001-02-26
DK0830864T3 (da) 2003-05-26
US6147072A (en) 2000-11-14
HU228178B1 (en) 2013-01-28
IL161833A0 (en) 2005-11-20
ATE231724T1 (de) 2003-02-15
TW541178B (en) 2003-07-11
RS49828B (sr) 2008-08-07
CO4900058A1 (es) 2000-03-27
EP0830864B9 (en) 2003-09-03
AU4411297A (en) 1998-04-14
DE69718731T2 (de) 2003-09-11
WO1998011897A1 (en) 1998-03-26
CN1230886A (zh) 1999-10-06
HUP9903905A3 (en) 2001-03-28
ZA977967B (en) 1999-03-04
PL332481A1 (en) 1999-09-13
CZ98799A3 (cs) 1999-12-15
AR008462A1 (es) 2000-01-19
NZ334168A (en) 2000-09-29
NO991381D0 (no) 1999-03-22
KR20000048518A (ko) 2000-07-25
CA2264941A1 (en) 1998-03-26
AU719033B2 (en) 2000-05-04
EG24660A (en) 2010-04-07
CA2264941C (en) 2008-11-18
CZ301154B6 (cs) 2009-11-18
NO319166B1 (no) 2005-06-27
PL190374B1 (pl) 2005-12-30
JP2001503031A (ja) 2001-03-06
EP0830864B1 (en) 2003-01-29
ES2191152T3 (es) 2003-09-01
YU15299A (sh) 2002-06-19
MY125564A (en) 2006-08-30
KR100532901B1 (ko) 2005-12-02
DE69718731D1 (de) 2003-03-06
HUP9903905A2 (hu) 2000-10-28
UA62937C2 (uk) 2004-01-15
HK1009755A1 (en) 1999-06-11
AU719033C (en) 2005-08-04
BR9711530A (pt) 1999-08-24
EA199900324A1 (ru) 1999-08-26
EP0830864A1 (en) 1998-03-25
PE110198A1 (es) 1999-01-21
NO991381L (no) 1999-03-22

Similar Documents

Publication Publication Date Title
CN1162156C (zh) 奥氮平与氟西汀在制备治疗精神病药物中的用途
CN1302207A (zh) 双相性精神障碍的联合治疗
CN1154496C (zh) 奥氮平和氟西汀在制备治疗对抗治疗的严重抑郁症的药物中的应用
CN1146567C (zh) 奥氮平二水合物d
CN1128788C (zh) 苄基(亚苄基)－内酰胺衍生物,它们的制备以及作为5－ht1a和/或5－ht1d受体的选择性拮抗剂(激动剂)的用途
CN1036652C (zh) 碱式季酰胺，其制备方法及其药物组合物
CN1156445C (zh) 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
CN1239497C (zh) 制备芳烷基和芳基亚烷基杂环的内酰胺及酰亚胺的中间体
CN1805938A (zh) 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
CN1113436A (zh) 药物反应的增效作用
CN1366881A (zh) 用雌激素激动剂/拮抗剂治疗某些癌症的方法
CN1361783A (zh) 噻唑并衍生物和含有它们的药物组合物
CN1117092C (zh) 氮杂双环化合物,其药物组合物及医药用途
CN1111986A (zh) 治疗肠应激综合症的异噁唑衍生物
CN1950348A (zh) 治疗中枢神经系统障碍的取代的吗啉化合物
CN1168631A (zh) 治疗抗性肿瘤的方法
CN88102018A (zh) 1-苯基-3-萘氧基丙胺
CN1750817A (zh) 米那普仑(1s,2r)对映体在药品制备方面的用途
CN1268949A (zh) 稠合噻吩化合物及其医药用途
CN1177356A (zh) 用作加压素拮抗剂的双环苯并吖庚因衍生物
CN1635877A (zh) 通过烟碱性受体激动剂和单胺能物质的联合作用治疗情感性精神障碍
CN1051990C (zh) 制备环取代的2－氨基－1,2,3,4－四氢化萘的方法
CN1054249A (zh) 磺酰苯胺衍生物及其在医药上的应用
CN1662544A (zh) 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
CN1639124A (zh) 作为毒蕈碱受体拮抗剂的氨基四氢萘衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040818